MADISON HEIGHTS, Mich.--(BUSINESS WIRE)--Nov. 30, 2004--I-Flow Corporation (NASDAQ: IFLO) announced today a national agreement with Aetna to make I-Flow's InfuSystem service for oncology therapy delivery available. InfuSystem's service is the safest and most effective method of chemotherapy delivery and helps physicians better manage their patients' therapy and monitor outcomes. InfuSystem is the nationwide leader in ambulatory infusion management services.

InfuSystem offers the most comprehensive system available for chemotherapy infusion, providing ambulatory infusion pumps and related disposable supplies from a variety of manufacturers while assuming regulatory functions to achieve overall efficiency and cost-effective clinical outcomes. InfuSystem enables oncologists to control the delivery of chemotherapy in patients and directly manage their progress without the need for patients to remain in a hospital setting or to receive treatment at home from a non-physician.

"We believe that Aetna's agreement with InfuSystem is further validation that our unique service provides a strong benefit to oncologists for their patients undergoing chemotherapy," said Steve Watkins, President of InfuSystem, a wholly-owned subsidiary of the I-Flow Corporation. "Aetna provides benefits in all 50 states ranging from small employers to those serving Fortune 1000 companies. This greatly broadens the scope of patients who can benefit from the continuity of care and efficacy that this method provides, offering some measure of relief and comfort for patients in the difficult situation of undergoing cancer treatment."

About InfuSystem

InfuSystem has over 18 years of experience supplying patients with external ambulatory infusion pumps. Our team provides management and support to enhance the lives of our patients and the communities we serve. As a leading company in infusion care, we stay on top of technology to offer the latest in equipment to better serve our patients.

About I-Flow Corporation

I-Flow Corporation (iflo.com) designs, develops and markets technically advanced, low-cost drug delivery systems and services that are redefining the standard of care by providing life-enhancing, cost-effective solutions for pain relief.

Certain disclosures made by the Company in this press release and in other reports and statements released by the Company are and will be forward-looking in nature, such as comments that express the Company's opinions about trends and factors that may impact future operating results. Disclosures that use words such as the Company "believes," "anticipates," or "expects" or use similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ from those expected, and readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to republish revised forward-looking statements to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures made by the Company in this release which seek to advise interested parties of the risks and other factors that affect the Company's business, as well as in the Company's periodic reports on Forms 10-K, 10-Q, and 8-K filed with the Securities and Exchange Commission. The risks affecting the Company's business include, among others: implementation of our direct sales strategy; dependence on our suppliers and distributors; reliance on the success of the home health care industry; our continuing compliance with applicable laws and regulations, such as the Food Drug and Cosmetics Act, and the FDA's concurrence with our management's subjective judgment on compliance issues; the reimbursement system currently in place and future changes to that system; competition in the industry; economic and political conditions in foreign countries; currency exchange rates; inadequacy of booked reserves; technological changes and product availability and acceptance. All such forward-looking statements, whether made in this release or elsewhere, should be considered in context with the various disclosures made by the Company about its business.

    CONTACT: Schwartz Communications
             Wendy Williams/Erin Walsh, 781-684-0770
             iflo@schwartz-pr.com
             or
             I-Flow Corporation
             Orlando Rodrigues, 949-206-2619
             orlandorodrigues@iflo.com

    SOURCE: I-Flow Corporation